Earlier, in Hypertension Device Therapy II, the author reviewed the 2013 ESH/ESC Guidelines for the Prevention and Treatment of Hypertension for the recommended tier of renal denervation (RDN) and carotid pressure receptor stimulation therapy for the treatment of patients with intractable hypertension, the level of evidence (Class IIb recommendation, Level C evidence), and their caveats. At the time, the author emphasizes the need to correct some misconceptions in order to prevent misinformation to patients and the general public. These possible misconceptions include: first, the role of device therapy for recalcitrant hypertension is relatively limited and cannot completely replace medications, much less do so once and for all; second, medication is still the mainstream treatment for hypertension and recalcitrant hypertension, and device therapy cannot replace medication, that is, we are still quite far from the era of true hypertension device therapy. Third, how to improve patients’ compliance with medication, improve patients’ blood pressure compliance rate, and strengthen the overall disease management of hypertension are still the long-term issues of hypertension prevention and control. Recently, Medtronic held a press conference to announce the latest study of the Simplicity HTN III Trial: transcatheter renal denervation failed to meet the primary efficacy endpoint of six-month blood pressure reduction, i.e., blood pressure did not decrease significantly in the RDN group compared to the sham-operated group. Thus, the once sensational RDN technique has collapsed and is likely to be relegated to the sidelines. In this regard, some scholars have published five points of enlightenment on the arduous journey of RDN from victory to defeat, which I share with my own experience and share with all patients. The first is that perfection to the point of almost distortion is false, and the SimplicityHTN study did not set up a sham surgery group as a control, and the data were so perfect that, in retrospect, one has to be suspicious; therefore, the results of any uncontrolled, unblinded study, no matter how statistically significant the comparison, are not convincing. This is the biggest reflection the study gives us. Second, the publicity can blind us to the fact that the results of the SimplicityHTN II Trial study were initially published with great fanfare by the ACC and AHA, which led to widespread concern and discussion, and even the CE was blindsided by it. The aftereffect was that even if it failed, it was listed by ACC as the top of the list of major cardiovascular events in 2014. Third, therapeutic lifestyle changes are the cornerstone and core of the prevention and treatment of hypertension and other cardiovascular diseases included. The prevailing view is that hypertension is actually an acquired disease triggered by the long-term effects of a poor lifestyle. In other words, strict control of poor lifestyle coupled with this long-term period is the safest, most effective, most direct, easiest and most economical way to effectively control hypertension. In other words, the key to hypertension prevention and control is to adhere to the four small things: keep your mouth shut, keep your legs open, get a good night’s sleep and relax your mind. If the patient does not have good compliance, can not correct the poor lifestyle, the clinician is also unable to help. Fourth, the principle of tendency to avoid harm. Catheter ablation is, after all, an injurious operation, and regardless of whether the damage to the sympathetic nervous system is permanently reversible, some tissue destruction will never be reversible. Whether the destruction of these normal tissues will stimulate complex physiopathological reactions of the body is still a matter of time. Therefore, the implementation of any invasive procedure must follow the basic principle of carefully weighing the pros and cons and the risks and benefits. Fifth, be alert to interventional bias. When encountering an urgent or complex clinical situation, it is difficult to clarify what is the most accurate strategy, and physicians always implement interventions according to preconceptions or personal experience, which is called bias. These selection biases, information biases, and intervention biases are often inherent and difficult to avoid. And the fact is that the increased risk of disease associated with the clinical management of chronic conditions such as hypertension and heart failure is no less than the risk of the disease itself. For example, if class I antiarrhythmic drugs are administered for arrhythmias such as premature ventricular beats, inappropriate pharmacological interventions may result in an indicated reduction in arrhythmias, but whether they result in a change in hard endpoints such as an eventual reduction in sudden cardiac death is not known and may be counterproductive. Thus, it is always customary to compare multiple arrhythmias to rogue thieves in society: they are difficult for the police to catch all of them; ideally, their removal would be neither sustainable nor in accordance with social laws. Sixth, the truth will be late, never absent. That is, the so-called foundation is not firm, the ground shakes. The original idea of RDN came from transsurgical renal sympathetic nerve dissection. The renal sympathetic nervous system is mainly located in the outer mesothelium of the renal artery, while transcatheter RDN ablation is a transcatheter renal artery endothelial treatment. Is ablation of punctate nerve endings the same as dissection of neurons and nerve fibers? How much do we know about the compensatory or stress response stimulated by nerve endings ablation, and how relevant are the multi-organ and multi-systemic protective effects of RDN? …… In conclusion, unlike the mirage version of hypertension vaccine, device therapy for hypertension is within reach and, despite the temporary losses, its after all a common ideal for all cardiologists and hypertensive patients. These temporary setbacks will not stop the path of scientific progress, and aspiring individuals around the world will overcome the obstacles and eventually usher in the spring of hypertension device therapy. Furthermore, although the RDN failure was a slap in the face to the reckless believers, it certainly earned all cardiologists another opportunity for self-analysis and introspection: all chronic disease categories such as hypertension, heart failure and atrial fibrillation, due to their etiologic diversity, can never be cured by the elimination of a single factor or the use of a single treatment. “If it is urgent, treat the symptoms; if it is slow, treat the root cause”, both the symptoms and the root cause, integrated prevention and control remain the necessary path for effective control of chronic non-communicable diseases.